In the position paper,1it was mentioned that the therapeutic options for dyspnea are oxygen, opioids, anxiolytics, and not-better-specified nonpharmaceutical intervention, basing this statement on a article2published 4 years ago. In these last years, several studies were, however, published on the use of noninvasive ventilation (NIV) in patients with do-not-intubate order, with end-stage disease and severe dyspnea and/or respiratory distress. In the two more recent studies,3–4 it was demonstrated that about half of the patients survived the episode of respiratory distress and were discharged from the hospital. Indeed, in a pilot investigation5 it was showed that in a large portion of patients with end-stage solid cancer admitted to a palliative care unit for acute respiratory distress, NIV was able to significantly reduce dyspnea after only 1 h of ventilation. A randomized international trial is in progress in 10 palliative care units in order to evaluate the effect of oxygen therapy alone or in combination with NIV, the main outcomes being the reduction in dyspnea and in the use of opioids. Again we congratulate the authors of the position statement for their efforts, but we also wish that the chest physicians will consider in future the possibility of using NIV in the palliative treatment of dyspnea as a peculiar and unique tool of the respiratory world.